The Microbe最新文献

{"title":"Antimicrobial and antibiofilm activity of curcumin against oral pathogens: Potential for periodontal treatment","authors":"Vijay M. Kumbar ,&nbsp;Malleswara Rao Peram ,&nbsp;Manohar S. Kugaji ,&nbsp;Sanjivini Patil ,&nbsp;Manjula Kambimath ,&nbsp;Shreya Magennavar ,&nbsp;Mehmuda Hussain ,&nbsp;Kishore G. Bhat ,&nbsp;Ramesh Paranjape","doi":"10.1016/j.microb.2025.100355","DOIUrl":"10.1016/j.microb.2025.100355","url":null,"abstract":"<div><div>Periodontitis, a prevalent oral disease, arises from a consortium of oral bacterial species that form biofilms on tooth surfaces, triggering host inflammatory responses and leading to clinical symptoms. Curcumin (CUR), a natural polyphenolic compound, has garnered significant attention for its therapeutic properties. This study investigates the antibacterial and antibiofilm activities of CUR against oral pathogens. Minimal inhibitory concentrations (MICs) and minimal bactericidal concentrations (MBCs), time-kill curves, anti-adhesion, and antibiofilm assays were performed against a panel of oral bacteria associated with dental caries and periodontal disease. The results demonstrate that CUR exhibits notable antimicrobial activity, with MIC and MBC values ranging from 15.62 to 31.25 µg/mL and 31.25–125 µg/mL, respectively, against various oral pathogens, including <em>S. mutans</em>, <em>P. intermedia</em>, and <em>A. actinomycetemcomitans</em>. Additionally, CUR showed significant antibiofilm activity, disrupting the formation and stability of oral bacterial biofilms, which are critical in conferring drug resistance to antimicrobial agents. The promising potential of curcumin for oral health underscores the need for further research to develop CUR-based formulations for oral healthcare regimens, potentially improving oral health outcomes.</div></div>","PeriodicalId":101246,"journal":{"name":"The Microbe","volume":"7 ","pages":"Article 100355"},"PeriodicalIF":0.0,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143912280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Screening and optimization of cyclodextrin glucanotransferase production by an alkaliphile Paenibacillus daejeonensis P-83","authors":"Dimple S. Pardhi ,&nbsp;Khushbu Rabadiya ,&nbsp;Rushikesh G. Joshi ,&nbsp;Vikram H. Raval ,&nbsp;Rakeshkumar R. Panchal ,&nbsp;Kiransinh N. Rajput","doi":"10.1016/j.microb.2025.100358","DOIUrl":"10.1016/j.microb.2025.100358","url":null,"abstract":"<div><div>Cyclodextrin glucanotransferase (CGTase, EC 2.4.1.19) is the member of starch degrading enzymes that catalyses an intramolecular transglycosylation reaction to produce cyclodextrins. CGTase producing 141 isolates were obtained from different agricultural fields (paddy, corn, potato, sorghum, and millet), gardens, and industrial waste soil samples. Amongst these 141, an alkaliphilic CGTase producing bacterial isolate <em>Paenibacillus daejeonensis</em> P-83 was selected. Although the CGTase showed the ability to produce α-, β-, and γ-cyclodextrins, the optimization studies were focused on β-CD production. One-factor-at-a-time (OFAT) increased the initial CGTase production from 1.05 U/ml to 2.76 U/ml with optimal conditions like, 3 % (w/v) water chestnut flour, 0.5 % (w/v) peptone, 0.5 % (w/v) yeast extract, 0.02 % (w/v) MgSO₄, 0.1 % (w/v) K₂HPO₄, pH 11 ± 0.2, 6 % (v/v) inoculum, and incubation at 30 °C ± 0.2 for 72 hours on a rotary shaker (150 rpm). The CGTase production was increased upto 5.23 U/ml by statistical optimization via Central Component Design (CCD) using three variables i.e., water chestnut flour (3.65 %; w/v), peptone (1.1 %; w/v), and yeast extract (0.5 %; w/v). The optimization process significantly increased the CGTase production by 2.55 and 4.9 times using OFAT and CCD, respectively.</div></div>","PeriodicalId":101246,"journal":{"name":"The Microbe","volume":"7 ","pages":"Article 100358"},"PeriodicalIF":0.0,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143890407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Computational design of novel diphtheria toxin inhibitors using natural products-based drug discovery","authors":"Adedoyin John-Joy Owolade ,&nbsp;Damilola Bodun ,&nbsp;Elijah Orimisan Akinbi ,&nbsp;Samson Ayorinde Oni ,&nbsp;Jeremiah Oluwamayowa Omojuyigbe ,&nbsp;Taiwo Waris Olatunji ,&nbsp;Ani Chibuike Sylvanus ,&nbsp;Ayodele Emmanuel Oke","doi":"10.1016/j.microb.2025.100359","DOIUrl":"10.1016/j.microb.2025.100359","url":null,"abstract":"<div><h3>Background of study</h3><div>Diphtheria, caused by <em>Corynebacterium diphtheriae,</em> is still a major global health concern, especially in resource-limited settings. Current antimicrobial agents target the bacterium specifically, but they do not neutralize the main virulence factor, the diphtheria toxin. Additionally, the emergence of antimicrobial resistance further reduces the effectiveness of current antimicrobial agents, highlighting the need for antimicrobial agents with minimal resistance. This study aims to discover novel small-molecule inhibitors that can directly bind and inhibit the diphtheria toxin, offering a strategic therapeutic approach beyond conventional antimicrobial regimens.</div></div><div><h3>Methodology</h3><div>A structure-based drug design approach was employed using a curated compound library containing 30,472 natural products. We then employed a series of rigorous computational approaches such as drug-likeness filtration, pharmacophore modeling, molecular docking, MM-GBSA analysis, and ADMET prediction to screen this extensive library of natural products. Furthermore, we used Molecular Dynamics (MD) simulations over 100 nano-seconds to validate the stability of the ligand-protein complex, ensuring the robustness of our findings.</div></div><div><h3>Results</h3><div>Out of the screened compounds, five novel drug candidates exhibited strong binding affinities with binding energies of −10.031 kcal/mol, −9.383 kcal/mol, −8.807 kcal/mol, −8.414 kcal/mol, and −7.870 kcal/mol respectively, surpassing the reference ligand, Ampicillin. Among these, ZINC000013396848 stands out with the highest docking score of <span><math><mo>−</mo></math></span>10.031 kcal/mol and a high energy binding energy of <span><math><mo>−</mo></math></span>75.557 kcal/mol, which supported their potential inhibitory efficacy against the diphtheria toxin. The pharmacokinetic profile of ZINC000013396848 and ZINC000085569420 exhibited low toxicity, including reduced risks of carcinogenicity, and hepatoxicity, positioning them as promising candidates for further investigation.</div></div><div><h3>Conclusion</h3><div>This study identifies ZINC000013396848 as a potent diphtheria toxin inhibitor with the highest docking profile and has been proven to be energetically stable when complex with the target protein. The exceptional performance of ZINC000013396848 in our study warrants further investigation for its potential use in both vitro and vivo studies.</div></div>","PeriodicalId":101246,"journal":{"name":"The Microbe","volume":"7 ","pages":"Article 100359"},"PeriodicalIF":0.0,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143878834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CRISPR Cas systems: From bacterial defense mechanisms to revolutionary tools reshaping genetic research and translation therapeutics","authors":"Kamran Saeed ,&nbsp;Faisal Ayub ,&nbsp;Muhammad Arshad Durrani ,&nbsp;Muhammad Mujahid","doi":"10.1016/j.microb.2025.100344","DOIUrl":"10.1016/j.microb.2025.100344","url":null,"abstract":"<div><div>The CRISPR-Cas systems, initially identified as bacterial defense mechanisms, have become innovative tools for genetic research and translational therapeutics. These systems are made up of clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated (Cas) proteins, which precisely target and cleave specific genome sequences, thus providing bacteria with immunity against viral infections. This review traces the evolution of CRISPR-Cas systems from their discovery as a bacterial defence mechanism to present uses in genetic engineering and beyond. The diversity of these systems, their structure and function, and the profound impact of these systems on genetic research, including their use in the creation of novel therapies for a variety of diseases, will be explored. In particular, this review discuss therapeutic applications of CRISPR in various neurodegenerative disorders (Alzheimer disease, Huntington’s disease and Parkinson’s disease), cardiovascular diseases, viral disorders including HIV, blood disorders (β-thalassemia, haemophilia and sickle cell anaemia), ocular disorders (Retinitis pigmentosa, Leber's congenital amaurosis, Aniridia, X-linked juvenile retinoschisis) mitochondrial disorders, Duchene muscular dystrophy and cancer along with the prospects concerning them. Furthermore, we discuss recent advancements, including novel Cas variants (CasΦ, CasX/Cas12f), precision editing technologies (base editing and prime editing), advanced delivery systems (nanoparticles, viral vectors), and emerging diagnostic platforms (SHERLOCK and DETECTR). Despite the extensive literature available on CRISPR-Cas systems, there remains a need for an updated review addressing recent developments, technological advancements, and future directions. This review aims to fill this gap by presenting an in-depth analysis of cutting-edge research, distinguishing itself from previous reviews by incorporating newly discovered CRISPR-Cas variants, emerging therapeutic strategies, and evolving regulatory landscapes.</div></div>","PeriodicalId":101246,"journal":{"name":"The Microbe","volume":"7 ","pages":"Article 100344"},"PeriodicalIF":0.0,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143874786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bacterial biofilm and its role in antibiotic resistance","authors":"Shabana Sharif,&nbsp;Ashok Kumar Yadav","doi":"10.1016/j.microb.2025.100356","DOIUrl":"10.1016/j.microb.2025.100356","url":null,"abstract":"<div><div>A biofilm is a dense aggregation of microbial cells encased in an auto-generated matrix of proteins, DNA, and polysaccharides. Bacterial biofilms result in chronic illnesses due to their increased resistance to antibiotics, disinfectants, and the body's immune system. Patients' morbidity and mortality are raised by biofilms because they give bacteria a barrier of defense and resistance to antibiotics. An oxygen and nutrient gradient from the top to the bottom layer of biofilms is another important feature of biofilms. The quiescent cells that cause some of the antibiotic resistances are associated with the gradients and they have doubled rates and lower metabolic activity. With early treatment or aggressive antibiotic prophylaxis, as well as ongoing suppressive therapy, infections caused due to biofilms can be prevented or cured. This review covers bacterial biofilm formation, composition of biofilm, development of antibiotic resistance and tolerance in bacteria due to biofilm formation, and the generation of persistent cells that produce antibiotic resistance in bacteria.</div></div>","PeriodicalId":101246,"journal":{"name":"The Microbe","volume":"7 ","pages":"Article 100356"},"PeriodicalIF":0.0,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143878829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship between skin and gut microbiota dysbiosis and inflammatory skin diseases in adult patients: A systematic review","authors":"Maria Fernanda Sanchez-Lopez ,&nbsp;Paula Alejandra Barrero-Caicedo ,&nbsp;Helen Melissa Olmos-Carval ,&nbsp;Andres Felipe Torres-Medina ,&nbsp;Juan Pablo Alzate-Granados","doi":"10.1016/j.microb.2025.100342","DOIUrl":"10.1016/j.microb.2025.100342","url":null,"abstract":"<div><h3>Introduction</h3><div>The skin and gut microbiota significantly contribute to the body's homeostasis by modulating immune responses and protecting against pathogens. Dysbiosis, an imbalance in microbial communities, is increasingly recognized in inflammatory skin diseases such as psoriasis, atopic dermatitis, and rosacea. These diseases are interconnected through the gut-skin axis, involving complex immunological and neuroendocrine mechanisms. Understanding this bidirectional interaction is crucial, as it implies that alterations in gut microbiota can impact skin health and vice versa.</div></div><div><h3>Objective</h3><div>This systematic review aims to evaluate the association between dysbiosis of skin and gut microbiota and inflammatory skin diseases in adult patients, and to assess the efficacy of various therapeutic interventions targeting microbiota dysbiosis.</div></div><div><h3>Methods</h3><div>A systematic search was conducted in MEDLINE, Embase, Cochrane Library, Scopus, and Web of Science to identify experimental studies and clinical trials exploring microbiota dysbiosis in adults with inflammatory skin diseases. Inclusion criteria were studies employing genetic sequencing or microbiological culture methods, along with interventions such as probiotics or fecal transplants.</div></div><div><h3>Results</h3><div>From the initial 1279 studies identified, 19 met the inclusion criteria. In patients with psoriasis, gut microbiota exhibited decreased Actinobacteria and increased Firmicutes, correlating with elevated inflammatory markers. Atopic dermatitis was characterized by reduced populations of beneficial bacteria, particularly Bifidobacterium and Lactobacillus, significantly associated with skin flare-ups and disease severity. Therapeutic interventions with probiotics demonstrated improvement in microbial diversity and a reduction in inflammation across several inflammatory skin conditions, including psoriasis and atopic dermatitis.</div></div><div><h3>Discussion</h3><div>The findings underscore the significant role microbial dysbiosis plays in the pathogenesis of inflammatory skin diseases. Microbiota modulation through probiotics and prebiotics emerges as a promising therapeutic approach. However, due to heterogeneity among reviewed studies, further controlled research is essential to confirm the long-term efficacy and mechanisms of microbiota-targeted interventions.</div></div>","PeriodicalId":101246,"journal":{"name":"The Microbe","volume":"7 ","pages":"Article 100342"},"PeriodicalIF":0.0,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143881474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unlocking the secrets of the hair microbiome: From scalp health to therapeutic advances","authors":"Jibon Kumar Paul ,&nbsp;Mahir Azmal ,&nbsp;Omar Faruk Talukder ,&nbsp;ANM Shah Newaz Been Haque ,&nbsp;Meghla Meem ,&nbsp;Ajit Ghosh","doi":"10.1016/j.microb.2025.100353","DOIUrl":"10.1016/j.microb.2025.100353","url":null,"abstract":"<div><div>The human microbiome, a complex and dynamic community of microorganisms abiding in and on the human body, plays a critical part in maintaining health and impacting complaints. This microbiome includes bacteria, fungi, viruses, and other microbes that are essential for various physiological processes such as digestion, immune function, and pathogen protection. Among the different microbiomes in the body, the hair follicle microbiome is a distinct and vital niche. It influences hair and scalp health, including hair growth, immune responses, and forestallment of pathogenic colonization, and is involved in conditions like dandruff, seborrheic dermatitis, and acne. Recent exploration has begun to uncover the composition and functional places of the hair follicle microbiome, revealing its active participation in maintaining hair and scalp health. This review provides a comprehensive overview of the hair follicle microbiome, discussing its composition, functional roles, and relations with the host, and exploring methods to study these microbial communities. It highlights the remedial potential of targeting the hair follicle microbiome in treating hair and scalp conditions and suggests unborn exploration directions in this field.</div></div>","PeriodicalId":101246,"journal":{"name":"The Microbe","volume":"7 ","pages":"Article 100353"},"PeriodicalIF":0.0,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143878831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative study of multidrug-resistant bacteria (MDRB) isolated from patients in different wards of a hospital during the post-COVID-19 period","authors":"Abhishek Ojha,&nbsp;Dwight Figueiredo,&nbsp;Shabnum Khan","doi":"10.1016/j.microb.2025.100350","DOIUrl":"10.1016/j.microb.2025.100350","url":null,"abstract":"<div><div>Antibacterial resistance (ABR) remains a global health threat in the 21^st century. This study aimed to examine the prevalence and distribution of multidrug-resistant bacteria (MDRB) isolated from patients in a tertiary care hospital during (2021) and post-COVID-19 (2022 and 2023) pandemic years. In the study, 100 patients were involved, with 85 % successfully discharged (p-value = &lt;0.00001), and 5 % deceased (p-value = &lt;0.00001). Microbiological and antibiotic susceptibility testing was performed on patient samples to determine MDRB and assess their resistance profiles. The outcomes exhibited an increase in MDRB prevalence in 2022 (standard error, SE, ± 0.0351 to ± 0.0936) compared to 2021 (SE ± 0.0380 to ± 0.0654) and 2023 (SE ± 0 to ± 0.1158). Gammaproteobacteria was predominant across the recovered samples. <em>Klebsiella pneumoniae</em> (40 %), <em>Escherichia coli</em> (28 %), <em>Citrobacter</em> sp. (19 %), <em>Acinetobacter</em> sp. (7 %), and <em>Pseudomonas aeruginosa</em> (6 %) were recognized as the predominant populations. The Shapiro-Wilk test for normality varied from 0.800 to 0.888 (<em>p-value</em> = &lt;0.081–0.351), while the Anderson-Darling test ranged from 0.343 to 0.511 (p-value = &lt;0.098–0.315). These MDRB exhibited Shannon and Simpson index values ranging from 1.138 to 1.508 and 0.643–0.775, respectively, with evenness values from 0.780 to 1.042, indicating microbial diversity in the patient samples. In antibiotic susceptibility testing, <em>Acinetobacter</em> sp. <em>Citrobacter</em> sp., <em>Pseudomonas aeruginosa</em>, <em>Escherichia coli</em>, and <em>Klebsiella pneumoniae</em> showed 100 % resistance to 23, 15, 14, 13, and 11 antibiotics, respectively. Further, compared to prior reports (de Souza et al., 2023, <em>p-value</em> = 0.00001, and Ruegsegger et al., 2022, <em>p-value</em> = &lt;0.0061), the percentages of MDRB, i.e. <em>Klebsiella pneumoniae</em> (40 %), <em>Escherichia coli</em> (28 %), and <em>Citrobacter</em> sp. (19 %), were significantly higher (<em>p-value</em> = &lt;0.00001) in this study. Overall, the MDRB distribution changed in prevalence across different years (2021 – 2023, during and post-COVID-19 pandemic) and medical conditions. Despite the high antibiotic resistance, the fatality rate in this study was lower than in other available reports, suggesting that effective recovery is possible with rapid and tailored treatment. These outcomes indicate the requirement for enhanced surveillance, monitoring, and targeted treatment strategies to manage ABR effectively.</div></div>","PeriodicalId":101246,"journal":{"name":"The Microbe","volume":"7 ","pages":"Article 100350"},"PeriodicalIF":0.0,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143868445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Virus-like particles: Innovative strategies for combatting emerging and re-emerging viral threats","authors":"Bugude Laxmi ,&nbsp;Palempalli Uma Maheswari Devi ,&nbsp;Thanjavur Naveen ,&nbsp;Viswanath Buddolla","doi":"10.1016/j.microb.2025.100351","DOIUrl":"10.1016/j.microb.2025.100351","url":null,"abstract":"<div><div>Virus-like particles (VLPs) are non-infectious nanostructures that closely mimic the architecture and surface features of native viruses while lacking genetic material. This structural resemblance, combined with their inherent safety, positions VLPs as powerful tools in addressing the growing challenges posed by emerging and re-emerging viral threats. This review highlights their significant contributions in three key areas: vaccine development, viral diagnostics, and environmental surveillance. In the field of vaccinology, VLPs have shown remarkable potential to elicit robust immune responses, making them suitable for designing multivalent and broad-spectrum vaccines, particularly against zoonotic and vector-borne viruses. In diagnostics, their use in assay development has significantly improved the sensitivity and specificity of viral detection, offering promise for rapid and accurate identification of pathogens. Moreover, VLPs are being increasingly explored in environmental monitoring systems, where they contribute to the early detection of viral pathogens in water and other ecological matrices. These applications not only enhance our understanding of virus transmission dynamics but also support public health preparedness. VLPs also serve as valuable tools for studying viral immune evasion mechanisms and host-pathogen interactions, contributing to our understanding of viral evolution. Their adaptability and multifunctionality suggest that VLPs will play an increasingly important role in global virology research, disease prevention, and pandemic preparedness.</div></div>","PeriodicalId":101246,"journal":{"name":"The Microbe","volume":"7 ","pages":"Article 100351"},"PeriodicalIF":0.0,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143868448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring biosurfactant production in Dyadobacter fermentans JDP9: Insights from genome sequencing and analysis","authors":"Jyoti Solanki ,&nbsp;Dhaval Patel ,&nbsp;Suresh Mesara ,&nbsp;M. Nataraj","doi":"10.1016/j.microb.2025.100345","DOIUrl":"10.1016/j.microb.2025.100345","url":null,"abstract":"<div><div>The present study examines the comprehensive analysis of the whole genome shotgun sequencing of <em>Dyadobacter fermentans</em> JDP9. The <em>Dyadobacter</em> genus is recognized for its synthesis of flexirubin; however, its capacity for biosurfactant (BS) production, particularly glycoprotein BS, has not been reported yet. A potential BS-producing <em>D. fermentans</em> JDP9 strain was isolated from hydrocarbon-contaminated soil. The BS was primarily characterized as a glycoprotein. The utilization of the Illumina platform for whole genome shotgun sequencing resulted in 2,469,724 high-quality reads assembled into 27 scaffolds, revealing a genome size of 7,979,294, GC content of 50.3 %, a Scaffold L50 value of 5, and a Scaffold N50 value of 522,766. The NCBI Prokaryotic Genome Annotation Pipeline identified 6,602 genes and 6,557 CDS. The systematic examination carried out by AntiSMASH, identified a total of 9 clusters, specifically the non-ribosomal peptide synthetase gene cluster. Herein, we proposed that the glycoprotein BS production is facilitated by enzymes involved in the dTDP-L-rhamnose biosynthetic pathway, including glucose-1-phosphate thymidylyltransferase, dTDP-glucose 4,6-dehydratase, and dTDP-4-dehydrorhamnose reductase present in the JDP9 strain genome. These enzymes contribute to generating dTDP-L-rhamnose, a crucial sugar moiety for glycosylation reactions. This study establishes a foundation for prospective investigations into glycoprotein BS production, presenting potential biotechnology implications.</div></div>","PeriodicalId":101246,"journal":{"name":"The Microbe","volume":"7 ","pages":"Article 100345"},"PeriodicalIF":0.0,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143876613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}